These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 4039929)
1. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia. Leprán I; Lefer AM Basic Res Cardiol; 1985; 80(2):135-41. PubMed ID: 4039929 [TBL] [Abstract][Full Text] [Related]
2. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium. Lefer AM; Mentley R; Sun JZ Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950 [TBL] [Abstract][Full Text] [Related]
4. Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. Burke SE; DiCola G; Lefer AM J Cardiovasc Pharmacol; 1983; 5(5):842-7. PubMed ID: 6195474 [TBL] [Abstract][Full Text] [Related]
5. Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia. Burke SE; Lefer DJ; Lefer AM Arch Int Pharmacodyn Ther; 1983 Sep; 265(1):76-84. PubMed ID: 6686001 [TBL] [Abstract][Full Text] [Related]
6. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia. Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270 [TBL] [Abstract][Full Text] [Related]
7. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Chakrabarty S; Thomas P; Sheridan DJ Eur Heart J; 1991 May; 12(5):583-9. PubMed ID: 1874258 [TBL] [Abstract][Full Text] [Related]
8. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Brezinski ME; Yanagisawa A; Darius H; Lefer AM Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159 [TBL] [Abstract][Full Text] [Related]
9. Preservation of ischemic myocardium by pinane thromboxane A2. Schrör K; Smith EF; Bickerton M; Smith JB; Nicolaou KC; Magolda R; Lefer AM Am J Physiol; 1980 Jan; 238(1):H87-92. PubMed ID: 7356037 [TBL] [Abstract][Full Text] [Related]
10. Salutary actions of thromboxane synthetase inhibition during global myocardial ischemia. Lefer AM; Messenger M; Okamatsu S Naunyn Schmiedebergs Arch Pharmacol; 1982 Nov; 321(2):130-4. PubMed ID: 6891441 [TBL] [Abstract][Full Text] [Related]
11. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. Burke SE; Lefer AM; Smith GM; Smith JB Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6681711 [TBL] [Abstract][Full Text] [Related]
12. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase. Davenport NJ; Goldstein RE; Feuerstein GZ J Cardiovasc Pharmacol; 1991 Apr; 17(4):641-6. PubMed ID: 1711633 [TBL] [Abstract][Full Text] [Related]
13. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion. Hock CE; Lefer AM Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540 [TBL] [Abstract][Full Text] [Related]
14. Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Smith EF; Lefer AM; Smith JB Can J Physiol Pharmacol; 1980 Mar; 58(3):294-300. PubMed ID: 7378931 [TBL] [Abstract][Full Text] [Related]
15. Studies on the protective effect of prostacyclin in acute myocardial ischemia. Ogletree ML; Lefer AM; Smith JB; Nicolaou KC Eur J Pharmacol; 1979 Jun; 56(1-2):95-103. PubMed ID: 467518 [TBL] [Abstract][Full Text] [Related]
16. Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Kim YD; Danchak RM; Heim KF; Lees DE; Myers AK Prostaglandins; 1993 Sep; 46(3):269-76. PubMed ID: 8234834 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. Tanabe M; Terashita Z; Nishikawa K; Hirata M J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970 [TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor-induced coronary constriction in the isolated perfused guinea pig heart and antagonistic effects of the PAF antagonist WEB 2086. Felix SB; Steger A; Baumann G; Busch R; Ochsenfeld G; Berdel WE J Lipid Mediat; 1990; 2(1):9-20. PubMed ID: 2133268 [TBL] [Abstract][Full Text] [Related]
19. TNF potentiates PAF-induced pulmonary vasoconstriction in the rat: role of neutrophils and thromboxane A2. Chang SW J Appl Physiol (1985); 1994 Dec; 77(6):2817-26. PubMed ID: 7896627 [TBL] [Abstract][Full Text] [Related]
20. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury. Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]